Streetbeat News

Stock Prices

MA

Over the past 5 years, Mastercard (NYSE:MA) has produced an average annual return of 15.65%, outperforming the market by 4.1% on an annualized basis. A $100 investment in Mastercard stock 5 years ago would be worth $206.54 today. Mastercard's market capitalization currently stands at $383.76 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

PYPL

B of A Securities has downgraded PayPal Holdings (NASDAQ:PYPL) from its previous rating to Neutral, with a new price target of $66.00, down from $77.00. Despite the downgrade, PayPal's shares have risen 3.33% in the last 24 hours to $59.85. The new price target suggests a potential upside of 10.28%. PayPal, known for its online payment solutions, had 435 million active accounts by the end of 2022 and owns the Venmo platform.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

HMC

Honda Motor Co (NYSE:HMC) has seen an 18.18% increase in short interest since its last report, with 2.07 million shares sold short, representing 0.13% of available shares. The short interest ratio is 1.5 days. While higher short interest can indicate bearish sentiment, it doesn't necessarily predict a price drop. Honda's short interest is below its peer group average of 11.69%.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

LRCX

Over the past 15 years, Lam Research (NASDAQ:LRCX) has produced an average annual return of 26.36%, outperforming the market by 14.76% on an annualized basis. A $100 investment in LRCX 15 years ago would be worth $3,201.17 today. The company currently has a market capitalization of $91.97 billion. The article highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

TEAM

Atlassian (NYSE:TEAM) has seen a 3.94% increase in short interest since its last report, with 3.26 million shares sold short, representing 2.11% of its float. The short interest is below the peer group average of 3.32%. While an increase in short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

OVV

JP Morgan has upgraded its rating of Ovintiv (NYSE:OVV) to Overweight with a new price target of $58.00, down from the previous $61.00. Ovintiv's shares are currently trading at $42.30, and the new price target suggests a potential upside of 37.12%. Ovintiv is an independent oil and gas producer with significant reserves and production levels.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

REPL

Barclays has maintained its Overweight rating on Replimune Group (NASDAQ:REPL) but reduced its price target from $50.00 to $13.00. Replimune's shares are currently trading at $6.77, and the new price target suggests a potential upside of 92.02%. Replimune is a clinical-stage biotech company focused on developing oncolytic immunotherapies for cancer treatment using its proprietary RPx platform.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

AZO

Raymond James has upgraded AutoZone (NYSE:AZO) to Strong Buy, raising the price target from $2850.00 to $3100.00. AutoZone's shares are currently trading at $2674.98, and the new price target suggests a potential upside of 15.89%. AutoZone is a leading seller of aftermarket automotive parts in the U.S., with a growing presence in Mexico and Brazil.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

FHN

Wells Fargo has maintained its Equal-Weight rating on First Horizon (NYSE:FHN) and increased its price target from $11.50 to $14.00. First Horizon's shares have risen 0.66% to $13.67, and the new target suggests a 2.42% upside. First Horizon, a regional bank with a strong presence in Tennessee, derives most of its revenue from banking operations and has a significant market share in deposits.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:00 pm

OPTN

OptiNose shares dropped following the announcement that the FDA has extended the review period for the supplemental new drug application of XHANCE by three months.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:57 pm